Thiazolopyridinone derivates as MCH receptor antagonists

Details for Australian Patent Application No. 2005316314 (hide)

Owner Eli Lilly and Company

Inventors Savin, Kenneth Allen; Beck, James Peter; Gardinier, Kevin Matthew; Ruble, James Craig; Amegadzie, Albert Kudzovi; Hembre, Erik James; Wakefield, Brian David

Agent Spruson & Ferguson

Pub. Number AU-B-2005316314

PCT Pub. Number WO2006/066174

Priority 60/637,143 17.12.04 US

Filing date 16 December 2005

Wipo publication date 22 June 2006

Acceptance publication date 23 June 2011

International Classifications

C07D 513/04 (2006.01) Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups , or

A61K 31/435 (2006.01) - having six-membered rings with one nitrogen as the only ring hetero atom

A61P 3/00 (2006.01) Drugs for disorders of the metabolism

Event Publications

21 June 2007 PCT application entered the National Phase

  PCT publication WO2006/066174 Priority application(s): WO2006/066174

23 June 2011 Application Accepted

  Published as AU-B-2005316314

20 October 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005316337-Tetrahydroisoquinoline compounds for treatment of CNS disorders

2005316313-Novel MCH receptor antagonists